Top

Published in:

01-07-2013 | Brief Report

Providing access to risk prediction tools via the HL7 XML-formatted risk web service

Authors: Jonathan Chipman, Brian Drohan, Amanda Blackford, Giovanni Parmigiani, Kevin Hughes, Phil Bosinoff

Published in: Breast Cancer Research and Treatment | Issue 1/2013

Abstract

Cancer risk prediction tools provide valuable information to clinicians but remain computationally challenging. Many clinics find that CaGene or HughesRiskApps fit their needs for easy- and ready-to-use software to obtain cancer risks; however, these resources may not fit all clinics’ needs. The HughesRiskApps Group and BayesMendel Lab therefore developed a web service, called “Risk Service”, which may be integrated into any client software to quickly obtain standardized and up-to-date risk predictions for BayesMendel tools (BRCAPRO, MMRpro, PancPRO, and MelaPRO), the Tyrer-Cuzick IBIS Breast Cancer Risk Evaluation Tool, and the Colorectal Cancer Risk Assessment Tool. Software clients that can convert their local structured data into the HL7 XML-formatted family and clinical patient history (Pedigree model) may integrate with the Risk Service. The Risk Service uses Apache Tomcat and Apache Axis2 technologies to provide an all Java web service. The software client sends HL7 XML information containing anonymized family and clinical history to a Dana-Farber Cancer Institute (DFCI) server, where it is parsed, interpreted, and processed by multiple risk tools. The Risk Service then formats the results into an HL7 style message and returns the risk predictions to the originating software client. Upon consent, users may allow DFCI to maintain the data for future research. The Risk Service implementation is exemplified through HughesRiskApps. The Risk Service broadens the availability of valuable, up-to-date cancer risk tools and allows clinics and researchers to integrate risk prediction tools into their own software interface designed for their needs. Each software package can collect risk data using its own interface, and display the results using its own interface, while using a central, up-to-date risk calculator. This allows users to choose from multiple interfaces while always getting the latest risk calculations. Consenting users contribute their data for future research, thus building a rich multicenter resource.

Available only for authorised users

Parmigiani G, Berry DA, Aguilar O (1998) Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158PubMedCrossRef

Tai YC, Domchek S, Parmigiani G, Chen S (2007) Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99(23):1811–1814PubMedCrossRef

Tai YC, Chen S, Parmigiani G, Klein AP (2008) Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res 10(2):401PubMedCrossRef

Katki HA, Blackford A, Chen S, Parmigiani G (2008) Multiple diseases in carrier probability estimation: accounting for surviving all cancers other than breast and ovary in BRCAPRO. Stat Med 27(22):4532–4548PubMedCrossRef

Katki HA (2007) Incorporating medical interventions into carrier probability estimation for genetic counseling. BMC Med Genet 8:13PubMedCrossRef

Chen S, Blackford A, Parmigiani G (2009) Tailoring BRCAPRO to Asian-Americans. J Clin Oncol 27(4):642–643PubMedCrossRef

Biswas S, Tankhiwale N, Blackford A, Barrera AMG, Ready K, Lu K, Amos CI, Parmigiani G, Arun B (2012) Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 133(1):347–355PubMedCrossRef

Chen S, Wang W, Broman KW, Katki HA, Parmigiani G (2004) Bayes-Mendel: an R Environment for Mendelian Risk Prediction. Stat Appl Genet Mol Biol 3:Article21

CaGene [http://www4.utsouthwestern.edu/breasthealth/cagene/]

10.

HughesRiskApps [http://www.hughesriskapps.com/]

11.

Ozanne EM, Loberg A, Hughes S, Lawrence C, Drohan B, Semine A, Jellinek M, Cronin C, Milham F, Dowd D, Block C, Lockhart D, Sharko J, Grinstein G, Hughes KS (2009) Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. Breast J 15(2):155–162PubMedCrossRef

12.

Health Level Seven International [http://www.hl7.org/]

13.

Tomcat [http://www.apache.org]

14.

To Obtain Risk Service [http://bcb.dfci.harvard.edu/bayesmendel/riskservice.php]

15.

King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646CrossRef

16.

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedCrossRef

17.

Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 Penetrance. J Clin Oncol 25(11):1329–1333PubMedCrossRef

18.

Parmigiani G, Chen S, Iversen ES Jr, Friebel TM, Finkelstein DM, Anton-Culver H, Ziogas A, Weber BL, Eisen A, Malone KE, Daling JR, Hsu L, Ostrander EA, Peterson LE, Schildkraut JM, Isaacs C, Corio C, Leondaridis L, Tomlinson G, Amos CI, Strong LC, Berry DA, Weitzel JN, Sand S, Dutson D, Kerber R, Peshkin BN, Euhus DM (2007) Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 14(7):441–450CrossRef

19.

Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, Watson P, Gruber S, Euhus D, Kinzler K, Jass J, Gallinger S, Lindor N, Casey G, Ellis N, Giardiello F, Offit K, Parmigiani G, The Colon Cancer Family Registry (2007) Prediction of germline mutations and cancer risk in the lynch syndrome. JAMA 296(12):1479–1487CrossRef

20.

Wang W, Chen S, Brune K, Hruban R, Parmigiani G, Klein A (2007) PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 25(11):1417–1422PubMedCrossRef

21.

Wang W, Niendorf K, Patel D, Blackford A, Marroni F, Sober AJ, Parmigiani G, Tsao H (2010) Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res 70(2):552–559PubMedCrossRef

22.

Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111–1130PubMedCrossRef

23.

Boughey J, Hartmann L, Anderson S, Degnim A, Vierkant R, Reynolds C, Frost M, Pankratz V (2010) Evaluation of the Tyrer–Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol 28(22):3591–3596PubMedCrossRef

24.

Freedman AN, Slattery ML, Ballard-Barbash R, Willis G, Cann B, Pee D, Gail MH, Pfeiffer RM (2009) A colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol 27(5):686–693PubMedCrossRef

25.

Risk Service Demo [http://bayesmendel.dfci.harvard.edu/risk]

26.

BayesMendel Lab [http://bcb.dfci.harvard.edu/bayesmendel/index.php]

Title: Providing access to risk prediction tools via the HL7 XML-formatted risk web service
Authors: Jonathan Chipman
Brian Drohan
Amanda Blackford
Giovanni Parmigiani
Kevin Hughes
Phil Bosinoff
Publication date: 01-07-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2605-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Clinical–pathologic significance of cancer stem cell marker expression in familial breast cancers

Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years’ follow-up

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients

Breast cancer characteristics and HIV among 1,092 women in Soweto, South Africa

Myeloid-derived suppressor cells in breast cancer

Ultrasound-guided fine-needle aspiration of suspicious nodes in breast cancer patients; selecting patients with extensive nodal involvement

Keynote webinar | Spotlight on antibody–drug conjugates in cancer